Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences

Drug Profile

Emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences

Alternative Names: Emtricitabine/tenofovir-disoproxil; Emtriva®/Viread®; FTC/TDF; TDF/FTC; Tenofovir disoproxil fumarate/emtricitabine; Truvada; TVD; Viread®/Emtriva®

Latest Information Update: 03 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Gador; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; Stendhal Mexico; University of Alberta; University of Washington
  • Class Antiretrovirals; Deoxyribonucleosides; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase III Hepatitis B
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 25 Oct 2019 National Institute of Allergy and Infectious Diseases plans a phase III trial for HIV infections (Prevention) in February 2020 (NCT04140266)
  • 04 Mar 2019 Efficacy and adverse events data from the phase III DISCOVER trial in HIV-1 infections presented at the 26th Conference on Retroviruses and Opportunistic Infections (CROI-2019)
  • 05 Dec 2018 Gilead offered Japan Tobacco to terminate the exclusive licenses for HIV drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top